Risk factors for oral methotrexate failure in patients with inflammatory polyarthritis: results from a UK prospective cohort study

BACKGROUND: Oral methotrexate (MTX) is the first-line therapy for patients with rheumatoid arthritis (RA). However, approximately one quarter of patients discontinue MTX within 12 months. MTX failure, defined as MTX cessation or the addition of another anti-rheumatic drug, is usually due adverse eve...

Descripción completa

Detalles Bibliográficos
Autores principales: Bluett, James, Sergeant, Jamie C., MacGregor, Alex J., Chipping, Jacqueline R., Marshall, Tarnya, Symmons, Deborah P. M., Verstappen, Suzanne M. M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5859656/
https://www.ncbi.nlm.nih.gov/pubmed/29554956
http://dx.doi.org/10.1186/s13075-018-1544-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5859656/
https://www.ncbi.nlm.nih.gov/pubmed/29554956
http://dx.doi.org/10.1186/s13075-018-1544-9

Ejemplares similares